已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Successful treatment of psoriasis-associated uveitis with ixekizumab after failure of secukinumab and risankizumab

医学 塞库金单抗 葡萄膜炎 眼科 皮肤病科 上巩膜炎 伊克泽珠单抗 银屑病 银屑病性关节炎 外科 巩膜炎
作者
Angelyn Chen Yin Lua,Soon‐Phaik Chee,Hazel H. Oon
出处
期刊:Singapore Medical Journal [Medknow]
被引量:1
标识
DOI:10.4103/singaporemedj.smj-2023-133
摘要

Dear Sir, Psoriasis is strongly associated with uveitis, a rare but serious ocular complication. We report a case of psoriasis-associated uveitis treated successfully with ixekizumab, an interleukin (IL)-17A monoclonal antibody, after failure of treatment with secukinumab and risankizumab. A 43-year-old Caucasian woman was seen for follow-up of psoriasis with psoriatic arthritis and uveitis. Skin and joint manifestations were minimal, but she was troubled by left eye painless vision blurring and floaters for 3 months. She had been on treatment with secukinumab for 6 years and was diagnosed with uveitis a year before. Treatment before secukinumab included topical corticosteroids, narrowband ultraviolet B therapy and cyclosporine. Secukinumab was subsequently switched to risankizumab due to residual psoriatic lesions and preference for reduced injection frequency. During her follow-up here, she had been on treatment with risankizumab for 10 months. She was referred to Ophthalmology for uveitis management. Ophthalmic examination found left eye corrected visual acuity of 20/50, mild conjunctival injection, small keratic precipitates, mild anterior chamber cells and flare, and broken posterior synechiae. Posterior segment findings included mild vitritis and disc hyperaemia with moderate macular oedema, confirmed on optical coherence tomography [Figure 1a]. Right eye examination was normal.Figure 1: Optical coherence tomography of the left eye: (a) before ixekizumab therapy (white arrow: macular oedema); and (b) 2 months after ixekizumab therapy, which shows resolution of macular oedema.These findings were consistent with left chronic anterior uveitis complicated by macular oedema. This improved with prednisolone acetate 1% eyedrops; however, tapering in the frequency of eyedrops resulted in uveitis flares. The patient’s nonsteroidal anti-inflammatory drug (NSAID) allergy precluded alternative eyedrops. Due to concern of potential ocular side effects with prolonged corticosteroid eyedrop therapy, risankizumab was switched to ixekizumab 80 mg monthly. After she received two subcutaneous injections of ixekizumab 80 mg over 2 months, there was complete resolution of left eye uveitis and macular oedema [Figure 1b], with improvement in visual acuity to 20/20. Corticosteroid eyedrops was stopped, and she was maintained only on ocular lubricants. Her skin condition remained stable with a psoriasis area and severity index score of 1.2. Psoriasis is a chronic immune-mediated disorder with cutaneous, joint, gastrointestinal and ocular manifestations. Uveitis, though rare in the general population, is estimated to affect 7%–20% of patients with psoriasis.[1] Symptoms include pain, eye redness, floaters and even devastating vision loss. It has been proposed that T-helper cell subsets Th-1 and Th-17 are activated in psoriasis and uveitis. The current standard of care for non-infectious uveitis is topical corticosteroid eyedrops or periocular corticosteroid injection, with cycloplegics. For resistant cases, therapeutic options include systemic corticosteroids or biologics. Among the biologics, anti-tumour necrosis factor agents have shown the most favourable outcomes so far.[2] The cytokine IL-17 has been detected in patients with active uveitis.[2] Ixekizumab prevents binding of IL-17A to the IL-17 receptor, attenuating the proinflammatory cascade causing keratinocyte proliferation and activation in psoriasis. It has shown efficacy in the treatment of plaque psoriasis and ankylosing spondylitis. Clinical trials of ixekizumab in the treatment of psoriasis-associated uveitis have not been registered. With regard to other monoclonal antibodies, there has been reported treatment success of non-infectious uveitis with ustekinumab, an IL-12/IL-23 inhibitor.[3] Secukinumab, another IL-17A inhibitor, has so far failed to demonstrate efficacy for uveitis recurrence over placebo (primary end point)[1] and may warrant higher intravenous doses.[4] Janus kinase inhibitors are another consideration in newer uveitis treatments, with favourable clinical response of ocular inflammation to tofacitinib and baricitinib reported.[5] Our case study demonstrates the potential of ixekizumab in the treatment of psoriasis-associated uveitis. Significant morbidity may be prevented with treatment of the uveitis and from cessation of corticosteroid eyedrops, limiting steroid-associated ocular side effects. With the emergence of anti-interleukin therapy for psoriasis, concurrent treatment of psoriasis and psoriasis-associated uveitis with biologics is promising. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jepsen完成签到 ,获得积分0
刚刚
CAOHOU完成签到,获得积分0
1秒前
成就海云完成签到,获得积分10
1秒前
zxy完成签到 ,获得积分10
1秒前
gqy完成签到,获得积分10
1秒前
有点鸭梨呀完成签到 ,获得积分10
1秒前
现代的严青完成签到 ,获得积分10
2秒前
2秒前
smile完成签到 ,获得积分10
3秒前
qq完成签到,获得积分10
3秒前
Danny完成签到,获得积分10
3秒前
一一完成签到 ,获得积分10
3秒前
白鹭思一骋完成签到 ,获得积分10
3秒前
lllllll完成签到 ,获得积分10
3秒前
bkagyin的应助被咎如天采纳,获得10
4秒前
dontcrybaby完成签到 ,获得积分10
4秒前
choup53完成签到 ,获得积分10
4秒前
隐形曼青的应助被酷炫的咪崽采纳,获得10
4秒前
冰凝完成签到,获得积分0
4秒前
腼腆的修杰完成签到,获得积分10
5秒前
Lan完成签到 ,获得积分10
5秒前
gqy发布了新的文献求助10
5秒前
依米完成签到 ,获得积分10
5秒前
ysws完成签到,获得积分10
5秒前
5秒前
Denmark完成签到 ,获得积分10
5秒前
Rjy完成签到,获得积分10
6秒前
cracro完成签到,获得积分10
6秒前
Zr完成签到,获得积分10
6秒前
林夏完成签到 ,获得积分10
6秒前
Yuther完成签到 ,获得积分10
7秒前
大江大河完成签到 ,获得积分10
7秒前
天仙狂醉完成签到 ,获得积分10
8秒前
车车发布了新的文献求助10
8秒前
小高完成签到 ,获得积分10
9秒前
鳄鱼宝宝发布了新的文献求助10
9秒前
月月完成签到 ,获得积分10
9秒前
kuaidi123完成签到 ,获得积分10
9秒前
zz完成签到,获得积分20
9秒前
莫力布林完成签到 ,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165620
求助须知:如何正确求助?哪些是违规求助? 9559174
关于积分的说明 21749120
捐赠科研通 7756384
什么是DOI,文献DOI怎么找? 3428967
关于科研通互助平台的介绍 2553246
邀请新用户注册赠送积分活动 2473556

今日热心研友

注:热心度 = 本日应助数 + 本日被采纳获取积分÷10